NCT04863742View on ClinicalTrials.gov

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

July 31, 2021

Study Completion Date

September 30, 2021

Conditions
Dry Eye Syndromes
Interventions
DRUG

Dextenza 0.4Mg Ophthalmic Insert

sustained released dexamethasone, 0.4mg

DRUG

Prednisolone Acetate

Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.

Trial Locations (1)

11717

RECRUITING

SightMD, LIASC, Brentwood

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.
All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Sight Medical Doctors PLLC

OTHER

NCT04863742 - Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL | Biotech Hunter | Biotech Hunter